Localized AdvancedOtsuka Pancreatic Study Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer Sponsor: Otsuka Patients will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD) or placebo Endpoint: Overall survival Eligibility: Click here Status: Recruiting Site: Blacktown Hospital Contact: Natalie Byrne
MM-398-07-03-01 A Randomized, Open Label Phase 3 Study of MM-398 Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Sponsor: Merrimack Pharmaceuticals The study is an open label, randomized phase 3 study of MM-398 versus 5-fluorouracil (5-FU) and leucovorin (also known as folinic acid) in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy Eligibility: Click here Status: Recruiting Site: Blacktown Hospital Contact: Joanna Jackson / Louise Franciso
|